

## Special Issue

# Advanced and Innovative Therapies of Dyslipidemia

### Message from the Guest Editor

Dyslipidemia is a widely recognized risk factor for atherosclerotic cardiovascular disease (ASCVD), and is a leading cause of morbidity and mortality. Although lipid-lowering treatments have been able to decrease the risk for ASCVD, the target LDL-C is not always achieved, mainly in patients with very high levels of LDL-C. In the last years, PCSK9 inhibitors (PCSK9i) have been more and more extensively implemented in clinical practice, providing great efficacy for decreasing LDL-C. However, PCSK9i are expensive, they are administered subcutaneously every 14 days and their long-lasting side effects are not known. Thus, there are continuous attempts to develop further novel, effective, and safe lipid-lowering treatments (bempedoic acid, selective PPAR alpha receptor modulators, etc.), including advanced therapies based on specific antisense oligonucleotide sequences targeting apolipoprotein CIII, lipoprotein (a), apolipoprotein B, or RNA silencing technique (PCSK9 mRNA). The aim of this Special Issue is to provide an update on the molecular mechanisms, as well as clinical and translational data on novel lipid-lowering treatments, including both reviews and experimental studies.

---

### Guest Editor

Prof. Dr. Matteo Di Minno

Department of Translational Medical Sciences, Federico II University, Naples, Italy

---

### Deadline for manuscript submissions

closed (15 March 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/79752](https://mdpi.com/si/79752)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).